Celebrating Black History Month by Supporting Equity in Clinical Trials
We work with large, de-identified data sets extracted and curated from the universe of electronic health records, claims systems, and myriad other sources. And yet, we are always brought back to the fact that amidst the data are the stories of people’s lives and their journeys of care.
The Importance of Using AI and Real World Data in Cancer Care with Corey Zankowski
In this episode of the Real World Talk podcast, Nick Ritter talks to Corey Zankowski, the senior vice president of oncology software solutions at Varian Medical Systems.
The first part of the conversation is dedicated to trends in the oncology community. Corey says the need for cancer care is expanding into emerging markets. The guest also notices the movement towards multidisciplinary care.
How Real World Data has Changed the Treatment Paradigm with Ankit Kansagra
In this episode of Real World Talk, Zoe Li talks to Ankit Kansagra. Dr. Kansagra is an oncologist and medical researcher at UT Southwestern in Dallas.
Real world data has changed the treatment paradigm, the doctor says. Clinical trials are the foundation, but it is crucial to look beyond basic labs. Going through previous cases leads to significant discoveries.
In this year-end episode of Real World Talk, host Emily Di Capua talks to COTA President and CEO Mike Doyle.
Mike describes how COTA has helped the FDA in its quest to gather data on COVID-19. COTA had access to data from 3,000 COVID-positive in-patients being treated at New Jersey-based partner Hackensack Meridian Health.
Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.
ASH 2020: Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
In collaboration with researchers from the University of Texas Southwestern Medical Center, this retrospective study uses RWD to explore treatment patterns and outcomes of functional high-risk multiple myeloma patients who relapse within 18 months of initial diagnosis.
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
In this retrospective observational cohort study involving 13 hospitals within the Hackensack Meridian Health network (NJ, USA), patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomized controlled trials are awaited.
ESMO IO 2019: Cost of Adverse Events (AEs) With Second-line (2L) Immuno-Oncology Agents (IO) and Chemotherapy (CHEMO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the Real World
In collaboration with Bristol-Myers Squibb, COTA investigated the incidence and cost of adverse events among aNSCLC patients treated with 2L immuno-oncology agents as compared to 2L chemotherapy, finding lower cost among patients treated with IO.
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
COTA was one of six organizations to participate in a collaboration to explore the consistency of real-world endpoints across diverse datasets and the potential validity of RWD to support regulatory and payer decision making.
ASCO 2019: Rates of Genotyping for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair in Metastatic Colon Cancer Patients: Gaps and Implications.
In collaboration with Guardant Health, COTA investigated the molecular testing rates of patients with metastatic colon cancer and found that <25% of our cohort received guideline recommended genotyping.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.